J. Goldman & Co’s iShares Biotechnology ETF IBB Stock Holding History

J. Goldman & Co’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,301	Closed	-$395K	–	801
2026 Q1	$389K	Buy	+2,301	New	+$393K	0.01%	537
2025 Q3	–	Sell	-5,600	Closed	-$764K	–	532
2025 Q2	$708K	Buy	+5,600	New	+$687K	0.02%	357
2024 Q3	–	Sell	-10,000	Closed	-$1.37M	–	528
2024 Q2	$1.37M	Buy	+10,000	New	+$1.33M	0.04%	281
2021 Q3	–	Sell	-2,556	Closed	-$418K	–	395
2021 Q2	$418K	Buy	2,556 +363	+17%	+$55.9K	0.02%	333
2021 Q1	$330K	Buy	2,193 +135	+7%	+$21.4K	0.01%	380
2020 Q4	$312K	Buy	+2,058	New	+$294K	0.02%	307
2017 Q4	–	Sell	-4,350	Closed	-$484K	–	384
2017 Q3	$484K	Buy	4,350 +600	+16%	+$64.1K	0.02%	272
2017 Q2	$388K	Buy	+3,750	New	+$369K	0.02%	251
2016 Q2	–	Sell	-1,500	Closed	-$130K	–	369
2016 Q1	$130K	Buy	+1,500	New	+$134K	0.01%	273

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

J. Goldman & Co's IBB Position: Q2 2026 in Review

J. Goldman & Co sold out of iShares Biotechnology ETF (IBB) in Q2 2026, closing a stake of 2,301 shares — an estimated $395K sold.

J. Goldman & Co first reported a position in IBB in Q1 2016 and held it in 9 quarters. The position peaked at $1.37M in Q2 2024. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

J. Goldman & Co reported no remaining iShares Biotechnology ETF position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 2,301 iShares Biotechnology ETF shares in Q2 2026, an estimated $395K.
J. Goldman & Co first reported a position in iShares Biotechnology ETF in Q1 2016 and held it in 9 quarters.
J. Goldman & Co's iShares Biotechnology ETF position peaked at $1.37M in Q2 2024.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.